Cancer gene mutation frequencies for the U.S. population

Abstract Mutations play a fundamental role in the development of cancer, and many create targetable vulnerabilities. There are both public health and basic science benefits from the determination of the proportion of all cancer cases within a population that include a mutant form of a gene. Here, we...

Full description

Saved in:

Bibliographic Details
Published in:	Nature communications 2021-10, Vol.12 (1), p.5961-5961, Article 5961
Main Authors:	Mendiratta, Gaurav, Ke, Eugene, Aziz, Meraj, Liarakos, David, Tong, Melinda, Stites, Edward C.
Format:	Article
Language:	eng
Subjects:	Cancer Epidemiology Epigenetics Genes Genetics Genomics Mutation p53 Protein Point mutation Public health
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Mutations play a fundamental role in the development of cancer, and many create targetable vulnerabilities. There are both public health and basic science benefits from the determination of the proportion of all cancer cases within a population that include a mutant form of a gene. Here, we provide the first such estimates by combining genomic and epidemiological data. We estimate KRAS is mutated in only 11% of all cancers, which is less than PIK3CA (13%) and marginally higher than BRAF (8%). TP53 is the most commonly mutated gene (35%), and KMT2C , KMT2D , and ARID1A are among the ten most commonly mutated driver genes, highlighting the role of epigenetic dysregulation in cancer. Analysis of major cancer subclassifications highlighted varying dependencies upon individual cancer drivers. Overall, we find that cancer genetics is less dominated by high-frequency, high-profile cancer driver genes than studies limited to a subset of cancer types have suggested.
ISSN:	2041-1723 2041-1723